Business Wire

KIRIN-HOLDINGS

20.5.2024 03:31:17 CEST | Business Wire | Press release

Share
Kirin Holdings will begin online sales of "Electric Salt Spoon", a spoon that uses electricity to enhance salty and umami taste*1, on May 20

Kirin Holdings Company, Limited (Kirin) will launch as a new business in the Health Science domain (Health Science business) a limited offering of 200 units of Electric Salt Spoon, which enhances the salty and umami taste of low-sodium foods with the power of electricity, on Monday, May 20, 2024 at its official online store (https://electricsalt.shop.kirin.co.jp/). In addition, a limited number of units will be available at Hands Inc. stores beginning in June.
This tableware-type device is equipped with technology that enhances the salty taste perceived when eating low-sodium foods by approximately 1.5 times*2,3. The technology was developed through joint research with the Meiji University Dr. Homei Miyashita Laboratory of the Department of Frontier Media Science, School of Interdisciplinary Mathematical Sciences (Miyashita Laboratory). Through this device, we aim to realize a society in which people can improve their lifestyle in a delicious way.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240519949395/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Target and current levels of salt intake (g/day) (Graphic: Business Wire)

1.

The 3rd Neurostimulation Interface Research Meeting. March 2023
"Influence on umami taste of the electric taste waveform that intensifies the saltiness of low-sodium foods"

2.

KIRIN news release on April 11, 2022 https://www.kirinholdings.com/jp/newsroom/release/2022/0411_01.html

3.

Change value of evaluation regarding saltiness intensity in a sample that imitates ordinary food and a sample with 30% less salt. Tested using chopsticks equipped with Electirc Salt technology (current 0.1~0.5 mA). Thirty-one men and women aged 40-65 years who are/were currently or have been reducing salt in the past were asked about the saltiness intensity they perceived when eating the test food, and 29 of the 31 respondents answered that the saltiness had increased.

The issue of "excessive salt intake" among Japanese people and dissatisfaction with the taste of low-sodium food
The daily salt intake of Japanese people aged 20 and over is 10.1g*4, which is much higher than the World Health Organization's (WHO) recommended salt intake of 5.0g*5. In addition, salt intake has not reached the "Healthy Japan 21 (2nd stage)*6 target for all age groups over 20 years old among both men and women*7. Target will be further lowered in the 3rd stage, making "excessive salt intake" the most important nutritional issue for Japanese people according to the Ministry of Health, Labor and Welfare.
In our questionnaire survey of persons who are currently eating a low-sodium diet or intend to do so*8, approximately 60% of the respondents felt issues exist in relation to low-sodium foods, and of those people, approximately 80% were dissatisfied with the taste. If low-sodium diets can be continued in better tasting way, it may lead to improvement in nutritional issues.

4.

Ministry of Health, Labour and Welfare National Health and Nutrition Survey 2019

5.

WHO Guidelines 2012

6.

Ministry of Health, Labour and Welfare Food Environment Strategy Initiative https://sustainable-nutrition.mhlw.go.jp/contents/sodium

7.

Ministry of Health, Labour and Welfare Basic Policy for the Comprehensive Promotion of the Health of the People
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kenkounippon21_00006.html

8.

Target: Men and women aged 40-79 living in the Tokyo metropolitan area (N=4,411) Format: Web survey Approximately 47% of all respondents are eating a low-sodium diet or intend to do so.

"Electric Salt Spoon" addresses social issues and consumer needs
"Electric Salt Spoon" is a tableware-type device developed based on the concept of "a life with delicious food for all people to address social issues and consumer needs for low-sodium food taste.
In our survey*9, respondents who are trying to reduce salt consumption ranked ramen noodles in first place and miso soup in second place as the "foods they would like to eat with a strong taste instead of a thin taste. This indicates that there is a need to eat ramen with a strong taste as a "reward" for refraining from eating it due to their efforts to reduce salt intake, as well as a need to enjoy foods that are eaten on a daily basis, such as "soup," in a delicious way.
Directed at commercialization of Electric Salt, we have continued to develop tableware such as chopsticks and bowls, but we decided to first develop and market a "spoon" in consideration of the technical characteristics and the meals for which there are high consumer needs.

9.

Kirin Survey Period: January 2022 Target: 120 men and women aged 30~69 who are trying to reduce salt intake Format: CLT survey, multiple responses allowed. Press release regarding the results of this research (Monday, April 11, 2022) https://www.kirinholdings.com/jp/newsroom/release/2022/0411_01.html

Product Overview, Sales Method and Developer's Comments 

Product

Product name

Electric Salt Spoon

Dimensions

Approx. W250 x D38 x H25 (mm)

Weight

Approx. 60g (excluding batteries)

Power Supply

3V lithium battery (CR2)

Price

19,800 yen (tax included)

Features

A weak electric current is passed from the tip of the spoon to the food to enhance the taste of the meal*, including salty and umami taste. We have improved the technology so that the spoon can be used naturally at the dining table and designed the device with a focus on ease of use and durability.

* There are individual differences in experience. Also, the feeling may vary depending on the dish.

How to use

Turn the power on with the switch on the handle of the spoon, select the desired intensity (4 levels), and use the spoon as you would a regular spoon.

Details

https://electricsalt.shop.kirin.co.jp/electricsalt-spoon/product/ES-S001/

* There are certain conditions under which this product may not be used (e.g. minors and persons fitted with a pacemaker or other medical electrical device). Please check the "Safety Precautions" on the official online store or on the product box.

Recommendation

It can be used with soups with lots of ingredients, curry, fried rice, food in a bowl, ramen noodles, and other meals in general.

 
Sales Method

1. Official Online Store (https://electricsalt.shop.kirin.co.jp/)

Initial sales volume

200 units (planned)

* Please apply from the product purchase page on the official online store.

* If the number of applications exceeds the number of units to be sold, sales will be conducted by lottery.

Application Period

Monday, May 20, 2024 - Sunday, June 2, 2024

* In case of lottery sales, all applicants will be notified on Thursday, June 6.

Shipping Schedule

Mid-June 2024

* Sales are scheduled to continue after June. We will announce it on the official Electric Salt online store in due course.

2. Hands Inc

Start of sales

June 2024 (Planned)
* For more information, please refer to the website/ press release of Hands Inc.
(URL: https://shinjuku.hands.net/item/7f/7f-14.html)

Developer's Comments
Ai SATO Health Science Business Division, New Business Group
People trying to reduce salt intake often stated, "I understand the importance of reducing salt intake, but it is too hard for me to continue." This prompted us to start research and development of Electric Salt in 2019, which finally led to the marketing of the product after more than 5 years.

I hope people who have difficulty starting or continuing salt reduction will use Electric Salt as a tool to enjoy a wide range of meals and enrich their dietary life.

Future development of "Electric Salt"
Kirin will continue to propose the development of tableware other than spoons and low-sodium food menus, and we will work with companies and local governments to expand the use of Electric Salt and its market. Electric Salt aims to provide services that enable consumers to enjoy eating healthy, delicious, and enjoyable foods and to realize a healthy and happy society.

About Kirin Holdings
(Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.
*: Creating Shared Value. Combined added value for consumers as well as for society at large.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240519949395/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye